Our top pick for
Nxt-ID Inc is a security & protection services business based in the US. Nxt-ID shares (NXTD) are listed on the NASDAQ and all prices are listed in US Dollars. Nxt-ID employs 19 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$2.61|
|52-week range||$0.30 - $3.44|
|50-day moving average||$0.46|
|200-day moving average||$0.76|
|Wall St. target price||$2.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.24|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-34.09%|
|1 month (2021-09-24)||625.00%|
|3 months (2021-07-23)||233.76%|
|6 months (2021-04-23)||235.91%|
|1 year (2020-10-23)||441.72%|
|2 years (2019-10-24)||467.14%|
|3 years (2018-10-24)||169.91%|
|5 years (2016-10-24)||3.36|
Valuing Nxt-ID stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Nxt-ID's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Nxt-ID's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $241,584.
The EBITDA is a measure of a Nxt-ID's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$10.4 million|
|Gross profit TTM||$8.2 million|
|Return on assets TTM||-6.33%|
|Return on equity TTM||-53.59%|
|Market capitalisation||$34.9 million|
TTM: trailing 12 months
There are currently 3.6 million Nxt-ID shares held short by investors – that's known as Nxt-ID's "short interest". This figure is 24.6% down from 4.8 million last month.
There are a few different ways that this level of interest in shorting Nxt-ID shares can be evaluated.
Nxt-ID's "short interest ratio" (SIR) is the quantity of Nxt-ID shares currently shorted divided by the average quantity of Nxt-ID shares traded daily (recently around 8.1 million). Nxt-ID's SIR currently stands at 0.45. In other words for every 100,000 Nxt-ID shares traded daily on the market, roughly 450 shares are currently held short.
However Nxt-ID's short interest can also be evaluated against the total number of Nxt-ID shares, or, against the total number of tradable Nxt-ID shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Nxt-ID's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Nxt-ID shares in existence, roughly 40 shares are currently held short) or 0.0952% of the tradable shares (for every 100,000 tradable Nxt-ID shares, roughly 95 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Nxt-ID.
Find out more about how you can short Nxt-ID stock.
We're not expecting Nxt-ID to pay a dividend over the next 12 months.
Nxt-ID's shares were split on a 1:10 basis on 11 September 2016. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Nxt-ID shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Nxt-ID shares which in turn could have impacted Nxt-ID's share price.
Over the last 12 months, Nxt-ID's shares have ranged in value from as little as $0.299 up to $3.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Nxt-ID's is 1.8836. This would suggest that Nxt-ID's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Nxt-ID, Inc. provides technology products and services for healthcare applications. It develops and markets solutions for payment, Internet of Things (IoT), and healthcare applications with experience in access control, biometric and behavior-metric identity verification, security and privacy, encryption and data protection, payments, miniaturization, and sensor technologies. The company, through its subsidiary, LogicMark LLC, manufactures and distributes non-monitored and monitored personal emergency response systems sold through healthcare durable medical equipment and monitored security dealers/distributors, and the United States Department of Veterans Affairs. It serves various end markets, including the security, healthcare, financial technology, and the IoT markets. Nxt-ID, Inc. was founded in 2011 and is based in Oxford, Connecticut.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.